These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35854080)

  • 21. Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.
    Wang H; Xie L; Song X; Wang J; Li X; Lin Z; Su T; Liang B; Huang D
    Front Immunol; 2022; 13():773001. PubMed ID: 35154100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment.
    Kawachi Y; Fujishima Y; Nishizawa H; Nagao H; Nakamura T; Akari S; Murase T; Taya N; Omori K; Miyake A; Fukuda S; Takahara M; Kita S; Katakami N; Maeda N; Shimomura I
    J Diabetes Investig; 2021 Aug; 12(8):1512-1520. PubMed ID: 33211396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations associated with functional disorder of xanthine oxidoreductase and hereditary xanthinuria in humans.
    Ichida K; Amaya Y; Okamoto K; Nishino T
    Int J Mol Sci; 2012 Nov; 13(11):15475-95. PubMed ID: 23203137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The double faced role of xanthine oxidoreductase in cancer.
    Chen MM; Meng LH
    Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin Resistance Associated with Plasma Xanthine Oxidoreductase Activity Independent of Visceral Adiposity and Adiponectin Level: MedCity21 Health Examination Registry.
    Kurajoh M; Fukumoto S; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Morioka T; Mori K; Imanishi Y; Inaba M; Emoto M
    Int J Endocrinol; 2019; 2019():1762161. PubMed ID: 32082372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Plasma Xanthine Oxidoreductase with Arterial Stiffness in Type 2 Diabetes with Liver Dysfunction.
    Ohira M; Tanaka S; Watanabe Y; Nakamura S; Oka R; Yamaguchi T; Ban N; Saiki A; Ishihara N; Murano T; Murase T; Nakamura T; Tatsuno I
    Am J Med Sci; 2022 Mar; 363(3):242-250. PubMed ID: 34619144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of plasma xanthine oxidoreductase activity with vascular endothelial function independent of serum uric acid level: MedCity21 health examination registry.
    Kurajoh M; Fukumoto S; Akari S; Murase T; Nakamura T; Ihara Y; Imai T; Nagata Y; Morioka T; Mori K; Imanishi Y; Watanabe T; Emoto M
    Int J Cardiol Heart Vasc; 2023 Oct; 48():101264. PubMed ID: 37680549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
    Battelli MG; Bortolotti M; Polito L; Bolognesi A
    Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma Xanthine Oxidoreductase Activity Associated with Glycemic Control in Patients with Pre-Dialysis Chronic Kidney Disease.
    Nakatani S; Ishimura E; Murase T; Nakamura T; Nakatani A; Toi N; Nishide K; Uedono H; Tsuda A; Kurajoh M; Yamada S; Mori K; Inaba M; Emoto M
    Kidney Blood Press Res; 2021; 46(4):475-483. PubMed ID: 34082427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.
    Ohtsubo T; Matsumura K; Sakagami K; Fujii K; Tsuruya K; Noguchi H; Rovira II; Finkel T; Iida M
    Hypertension; 2009 Oct; 54(4):868-76. PubMed ID: 19667249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
    Chen C; Lü JM; Yao Q
    Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of allopurinol on uric acid concentrations, xanthine oxidoreductase activity and oxidative stress in broiler chickens.
    Carro MD; Falkenstein E; Radke WJ; Klandorf H
    Comp Biochem Physiol C Toxicol Pharmacol; 2010 Jan; 151(1):12-7. PubMed ID: 19654053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
    Shibata Y; Shirakabe A; Okazaki H; Matsushita M; Goda H; Shigihara S; Asano K; Kiuchi K; Tani K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
    Heart Vessels; 2020 Oct; 35(10):1390-1400. PubMed ID: 32342210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overnight changes in uric acid, xanthine oxidoreductase and oxidative stress levels and their relationships with sleep-disordered breathing in patients with coronary artery disease.
    Shimizu M; Kasai T; Naito R; Sato A; Ishiwata S; Yatsu S; Shitara J; Matsumoto H; Murata A; Kato T; Suda S; Hiki M; Kuwabara M; Murase T; Nakamura T; Daida H
    Hypertens Res; 2023 Oct; 46(10):2293-2301. PubMed ID: 37258622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Xanthine oxidoreductase: One enzyme for multiple physiological tasks.
    Bortolotti M; Polito L; Battelli MG; Bolognesi A
    Redox Biol; 2021 May; 41():101882. PubMed ID: 33578127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure.
    Otaki Y; Watanabe T; Kinoshita D; Yokoyama M; Takahashi T; Toshima T; Sugai T; Murase T; Nakamura T; Nishiyama S; Takahashi H; Arimoto T; Shishido T; Miyamoto T; Kubota I
    Int J Cardiol; 2017 Feb; 228():151-157. PubMed ID: 27865177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Xanthine oxidoreductase in cancer: more than a differentiation marker.
    Battelli MG; Polito L; Bortolotti M; Bolognesi A
    Cancer Med; 2016 Mar; 5(3):546-57. PubMed ID: 26687331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of plasma xanthine oxidoreductase activity in patients with heart failure with atrial fibrillation.
    Watanabe K; Arimoto T; Watanabe T; Otaki Y; Murase T; Nakamura T; Kobayashi Y; Aono T; Saito Y; Koyama K; Hashimoto N; Kutsuzawa D; Kato S; Tamura H; Nishiyama S; Takahashi H; Watanabe M
    J Cardiol; 2023 May; 81(5):469-475. PubMed ID: 36822544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of the Inhibition Mechanism of Xanthine Oxidoreductase by Oxipurinol: A Computational Study.
    Maghsoud Y; Dong C; Cisneros GA
    J Chem Inf Model; 2023 Jul; 63(13):4190-4206. PubMed ID: 37319436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase.
    Sekine M; Okamoto K; Ichida K
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.